AstraZeneca has paused a 200 million pound sterling ($271 million) investment in its Cambridge, England research site, a ...

The pause is the latest blow to the U.K.’s biotech industry, which is still reeling from Merck’s recently announced R&D ...

Like approved Alzheimer’s meds Kisunla (donanemab) and Leqembi (lecanemab), as well as the discontinued Aduhelm (aducanemab), ...

With its head of U.S. business Julie Kim sliding up to the CEO spot next June, Takeda has locked in a replacement in Rhona ...

Researchers at Mass General Brigham in Boston have designed a custom gene editing technique that corrected the mutation ...

FibroGen has agreed to pay $1.25 million to the Securities and Exchange Commission (SEC) to address allegations that the ...

Not all cardiac arrests can be treated with an electric shock. In fact, most of them—about 80%—are ineligible for ...

Less than two years after breaking ground on a ballyhooed 1 billion pound sterling ($1.31 billion) R&D center and future U.K.

Capsida Biotherapeutics has paused a gene therapy trial after the first patient died. | Capsida Biotherapeutics has paused a ...

Philips and Masimo are renewing their years-long collaboration in patient monitoring, with what they describe as an expanded ...

What’s the best way to spend $2 billion? That’s the pleasant problem facing oncology legend Brian Druker, M.D., as he ...

After previously delaying its decision date, the FDA has outright rejected Saol Therapeutics’ investigational treatment for ...